Payment overview · 2025
General Payments
$284.89
13 reported records · 9 companies
Healthcare provider profile · identity verified
Devi Kathleen Pierce, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CORYDON, IN · NPI 1144218496
Verified facts
What the public records show
CMS Open Payments records show Devi Kathleen Pierce, MD received $284.89 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.40 | 21.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.37 | 19.8% | 3 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $34.23 | 12.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.35 | 10.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.97 | 8.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.24 | 8.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.10 | 7.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.10 | 6.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.13 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $284.89 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.36 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.36 | 2 | 2025 |
Source payment records
|
|||||
| Iovera Normalized: iovera |
Device | Pacira Pharmaceuticals Incorporated | $34.23 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
232 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 598 | 76 |
| Gabapentin | Gabapentin | 517 | 86 |
| Omeprazole | Omeprazole | 498 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 469 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 408 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 86 |
| Lisinopril | Lisinopril | 390 | 102 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 380 | 39 |
| Montelukast Sodium | Montelukast Sodium | 354 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 331 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 302 | 73 |
| Metformin Hcl | Metformin Hcl | 298 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 68 |
| Glimepiride | Glimepiride | 282 | 59 |
| Losartan Potassium | Losartan Potassium | 278 | 68 |
| Potassium Chloride | Potassium Chloride | 272 | 70 |
| Furosemide | Furosemide | 271 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 250 | 45 |
| Celecoxib | Celecoxib | 242 | 47 |
| Jardiance | Empagliflozin | 232 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 219 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 218 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 212 | 44 |
| Amitriptyline Hcl | Amitriptyline Hcl | 211 | 38 |
| Trazodone Hcl | Trazodone Hcl | 209 | 42 |
| Meloxicam | Meloxicam | 205 | 62 |
| Tramadol Hcl | Tramadol Hcl | 204 | 36 |
| Pregabalin | Pregabalin | 199 | 46 |
| Alendronate Sodium | Alendronate Sodium | 193 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 193 | 30 |
| Prednisone | Prednisone | 182 | 77 |
| Diclofenac Sodium | Diclofenac Sodium | 181 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 177 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 166 | 31 |
| Ozempic | Semaglutide | 149 | 23 |
| Alprazolam | Alprazolam | 145 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 141 | 32 |
| Simvastatin | Simvastatin | 139 | 32 |
| Buspirone Hcl | Buspirone Hcl | 130 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 130 | 23 |
| Eliquis | Apixaban | 129 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 128 | 17 |
| Sertraline Hcl | Sertraline Hcl | 127 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 23 |
| Fluconazole | Fluconazole | 124 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 119 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 118 | 25 |
| Carvedilol | Carvedilol | 112 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 25 |
| Clonazepam | Clonazepam | 104 | suppressed |
| Famotidine | Famotidine | 101 | 22 |
| Spironolactone | Spironolactone | 101 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 22 |
| Propranolol Hcl | Propranolol Hcl | 95 | 23 |
| Sucralfate | Sucralfate | 92 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 17 |
| Bupropion Xl | Bupropion Hcl | 88 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 19 |
| Allopurinol | Allopurinol | 81 | 24 |
| Roflumilast | Roflumilast | 81 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 78 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 13 |
| Januvia | Sitagliptin Phosphate | 75 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 75 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 75 | 23 |
| Baclofen | Baclofen | 73 | 17 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 72 | 15 |
| Glipizide | Glipizide | 70 | 16 |
| Meclizine Hcl | Meclizine Hcl | 69 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Cefdinir | Cefdinir | 67 | 48 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 18 |
| Bumetanide | Bumetanide | 66 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 66 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 65 | 13 |
| Atenolol | Atenolol | 63 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 62 | 16 |
| Xarelto | Rivaroxaban | 62 | 13 |
| Azithromycin | Azithromycin | 61 | 52 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 14 |
| Metformin Hcl Er | Metformin Hcl | 61 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 41 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 59 | 28 |
| Ezetimibe | Ezetimibe | 59 | 15 |
| Donepezil Hcl | Donepezil Hcl | 58 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 57 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 14 |
| Myrbetriq | Mirabegron | 55 | 11 |
| Levemir Flexpen | Insulin Detemir | 54 | 13 |
| Topiramate | Topiramate | 54 | suppressed |
| Levofloxacin | Levofloxacin | 53 | 35 |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Primidone | Primidone | 51 | suppressed |
| Linzess | Linaclotide | 50 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 15 |
| Lorazepam | Lorazepam | 48 | 11 |
| Nitroglycerin | Nitroglycerin | 48 | 19 |
| Nystatin | Nystatin | 45 | 21 |
| Risperidone | Risperidone | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 11 |
| Ibuprofen | Ibuprofen | 44 | 12 |
| Hydrocortisone | Hydrocortisone | 42 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 22 |
| Pilocarpine Hcl | Pilocarpine Hcl | 37 | 14 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 15 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 33 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 21 |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 11 |
| Gemtesa | Vibegron | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 13 |
| Carbamazepine Er | Carbamazepine | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Acyclovir | Acyclovir | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 12 |
| Naproxen | Naproxen | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.89 · 13 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, Iovera, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error